ACADIA PHARMACEUTICALS INC's ticker is ACAD and the CUSIP is 004225108. A total of 166 filers reported holding ACADIA PHARMACEUTICALS INC in Q1 2014. The put-call ratio across all filers is 0.08 and the average weighting 0.3%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q4 2016 | $132,000 | -7.7% | 4,580 | +2.2% | 0.00% | -20.0% |
| Q3 2016 | $143,000 | -12.3% | 4,480 | -10.6% | 0.01% | -16.7% |
| Q2 2016 | $163,000 | +17.3% | 5,010 | +0.8% | 0.01% | 0.0% |
| Q1 2016 | $139,000 | -28.4% | 4,969 | -8.5% | 0.01% | -33.3% |
| Q4 2015 | $194,000 | +30.2% | 5,430 | +20.7% | 0.01% | -25.0% |
| Q3 2015 | $149,000 | -28.7% | 4,500 | -10.0% | 0.01% | -20.0% |
| Q2 2015 | $209,000 | -14.0% | 5,000 | -32.9% | 0.02% | -11.8% |
| Q1 2015 | $243,000 | 0.0% | 7,450 | -2.6% | 0.02% | -34.6% |
| Q4 2014 | $243,000 | +84.1% | 7,650 | +43.0% | 0.03% | +62.5% |
| Q3 2014 | $132,000 | +9.1% | 5,350 | 0.0% | 0.02% | 0.0% |
| Q2 2014 | $121,000 | -53.5% | 5,350 | -50.0% | 0.02% | -15.8% |
| Q1 2014 | $260,000 | +94.0% | 10,700 | +100.0% | 0.02% | -5.0% |
| Q4 2013 | $134,000 | -13.0% | 5,350 | -4.5% | 0.02% | -25.9% |
| Q3 2013 | $154,000 | +8.5% | 5,600 | -28.2% | 0.03% | -3.6% |
| Q2 2013 | $142,000 | – | 7,800 | – | 0.03% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Finepoint Capital LP | 556,553 | $11,598,565 | 5.78% |
| Baker Brothers Advisors | 42,864,612 | $893,298,514 | 5.15% |
| RTW INVESTMENTS, LP | 11,576,537 | $241,255,031 | 5.09% |
| Palo Alto Investors LP | 2,405,793 | $50,136,726 | 4.74% |
| Birchview Capital, LP | 240,400 | $5,009,936 | 4.26% |
| EcoR1 Capital, LLC | 5,991,479 | $124,862,422 | 4.21% |
| EMERALD ADVISERS, LLC | 1,681,052 | $35,033,124 | 1.70% |
| EMERALD MUTUAL FUND ADVISERS TRUST | 1,303,988 | $27,175,110 | 1.64% |
| INTERNATIONAL BIOTECHNOLOGY TRUST PLC | 179,702 | $3,739,599 | 1.26% |
| SECTOR GAMMA AS | 179,785 | $3,746,719 | 0.96% |